Klarifar

Clarithromycin, the active ingredient in Klarifar, is a macrolide antibiotic presented as an oral tablet for oral use. It treats bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis and skin and soft‑tissue infections in adult patients and is administered orally, offering a convenient option for outpatient therapy.

GNH USA supplies Klarifar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows Good Distribution Practice and complies with EU regulatory standards, ensuring product quality for global healthcare providers.

Clarithromycin is a macrolide antibiotic used to treat infections of the respiratory tract, sinuses and skin. It is effective against a broad range of Gram‑positive and some Gram‑negative bacteria.

- Community‑acquired pneumonia: reduces bacterial load, improves cough, fever and oxygenation, and accelerates recovery in adult patients. - Acute bacterial sinusitis: alleviates sinus pressure, nasal discharge and facial pain while promoting rapid eradication of the infecting organisms. - Skin and soft‑tissue infections: eradicates causative bacteria, reduces erythema and swelling, and supports healing of cellulitis, abscesses and wound infections.

Clarithromycin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset that often resolves without treatment. - Diarrhea: loose stools that may be transient. - Abdominal pain: cramping or discomfort in the abdomen. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate headache.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - QT prolongation: cardiac rhythm changes that can lead to arrhythmia. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Hematologic abnormalities: neutropenia or eosinophilia.

When prescribing clarithromycin, clinicians should consider several precautionary measures to ensure safe use. - Assess liver function: evaluate hepatic enzymes before initiating therapy. - Review cardiac history: avoid use in patients with known QT prolongation or arrhythmias. - Monitor drug interactions: check for concomitant use of drugs that affect CYP3A4 metabolism. - Use with caution in renal impairment: dose adjustment may be required in severe dysfunction. - Avoid in patients with known hypersensitivity to macrolides: discontinue if allergic reactions occur. - Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Clarithromycin interacts with several medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Statins (e.g., simvastatin, lovastatin): risk of severe myopathy and rhabdomyolysis. - Certain antiarrhythmics (e.g., amiodarone): may cause dangerous QT prolongation. - Ergot derivatives (e.g., ergotamine): can precipitate ergot toxicity. - Pimozide: increased plasma levels leading to neurotoxicity. - Cisapride: heightened risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., carbamazepine, midazolam): may have altered plasma concentrations. - Warfarin: potential increase in INR, requiring closer monitoring. - Oral contraceptives: possible reduction in contraceptive effectiveness. - Digoxin: may increase serum levels, necessitating dose adjustment. - Antacids containing aluminum or magnesium: can reduce clarithromycin absorption.